[3-(4-methoxy-phenyl)-3H-[1,2,3]triazolo[4_,5-d]pyrimidin-5-yl]-(1-phenyl-1H-pyrazol-4-yl)-amine | 1448692-77-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [3-(4-methoxy-phenyl)-3H-[1,2,3]triazolo[4_,5-d]pyrimidin-5-yl]-(1-phenyl-1H-pyrazol-4-yl)-amine
• 英文别名: 3-(4-methoxyphenyl)-N-(1-phenylpyrazol-4-yl)triazolo[4,5-d]pyrimidin-5-amine
• CAS: 1448692-77-0
• 化学式: C₂₀H₁₆N₈O
• 分子量: 384.4
• InChiKey: AYMRPRCQOADZMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  95.6
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (2-chloro-5-nitro-pyrimidin-4-yl)-(4-methoxy-phenyl)-amine 在 硫酸 、 palladium on activated charcoal 、 水 、 氢气 、 N,N-二异丙基乙胺 、 sodium nitrite 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 32.0h， 生成 [3-(4-methoxy-phenyl)-3H-[1,2,3]triazolo[4_,5-d]pyrimidin-5-yl]-(1-phenyl-1H-pyrazol-4-yl)-amine
  参考文献：
  名称：

  [EN] TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES
  [FR] DÉRIVÉS DE TRIAZOLO[4,5-D]PYRIMIDINE

  摘要：

  式（I）中R1和R2具有索引中指示的含义的化合物是GCN2的抑制剂，可用于治疗癌症。

  公开号：

  WO2013110309A1

文献信息

• TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES
  申请人：Merck Patent GmbH

  公开号：US20140378431A1

  公开（公告）日：2014-12-25

  Compounds of the formula I in which R 1 and R 2 have the meanings indicated in Claim 1 , are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

  公式I中，其中R1和R2的含义如权利要求1所示的化合物是GCN2的抑制剂，可用于治疗癌症等疾病。
• COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS
  申请人：BROWN Dennis M.

  公开号：US20160067241A1

  公开（公告）日：2016-03-10

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to naphthalimides such as amonafide or analogs, derivatives, or prodrugs thereof.
• US9409914B2
  申请人：——

  公开号：US9409914B2

  公开（公告）日：2016-08-09
• [EN] COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS<br/>[FR] COMPOSITIONS ET PROCÉDÉS PERMETTANT D'AMÉLIORER LE BÉNÉFICE THÉRAPEUTIQUE DES COMPOSÉS CHIMIQUES ADMINISTRÉS DE MANIÈRE SUBOPTIMALE COMPRENANT DES NAPHTALIMIDES SUBSTITUÉS TELS QUE L'AMONAFIDE POUR LE TRAITEMENT DES MALADIES IMMUNOLOGIQUES, MÉTABOLIQUES, INFECTIEUSES ET INFECTIEUSES OU HYPERPROLIFÉRATIVES ET NÉOPLASTIQUES.
  申请人：BROWN DENNIS M

  公开号：WO2014179528A2

  公开（公告）日：2014-11-06

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to naphthalimides such as amonafide or analogs, derivatives, or prodrugs thereof.
• [EN] HETEROCYCLIC GCN2 MODULATORS<br/>[FR] MODULATEURS DE GCN2 HÉTÉROCYCLIQUES
  申请人：HIBERCELL INC

  公开号：WO2021222147A1

  公开（公告）日：2021-11-04

  The invention relates to methods of using modulators of GCN2 and compositions thereof, in the treatment of cancers and other diseases and disorders associated with GCN2 activation, said modulators having the Formulae I, II, III, IV, V, VI, VII, and/or VIII.